A new hope for OsteoArthritic patients


Awarding a European prize is equivalent to a validation of the Technology readiness level (TRL) of the project by an independent body (EASME).

2017 H2020 SME INSTRUMENT phase-2 Topic :SMEInst-03-2017. European commission


2015 H2020 SME INSTRUMENT phase-1 Topic : BIOTEC-5a2015. European commission


2015 17th i-Lab “Créadev” BPI France


2013 15th “émergence” OSEO/BPI


2013 – Innovation Days One of 15 finalists “Innovation Prize” Universal Biotech.

Contact Info

Parc scientifique Biocitech
102 Avenue Gaston Roussel
Batiment Pasteur Secteur 2169
93230 Romainville - France

56 Boulevard de la Mission Marchand - 92400 Courbevoie France

Phone: +33 1 43 34 89 90

Mobile: +33 6 60 90 41 24

27 07, 2020

2020 – BioJapan Expo

July 27th, 2020|0 Comments


Regulaxis gets confirmed the relevance of it Asian international development plans
Despite troubled times due to Covid lockdowns
After being successfully selected by EU again to get sponsored participation at “BioJapan” Expo   in Yokohama, next October 2020

7 07, 2020


July 7th, 2020|0 Comments

Regulaxis’ President Claude Carelli  participated to the  interview on B SMART
The 1st meeting dedicated to small and medium-sized businesses.

At the microphone of Jean-Marc Sylvestre, Claude Carelli expose Regulaxis activity, their strategy, their needs and objectives.


A program in partnership with BPI France at 1 p.m. and 8:30 p.m. on B SMART.

3 07, 2020

PLOS ONE – Publication

July 3rd, 2020|0 Comments

Regulaxis is proud to announce the publication to the In Vivo study, on rat model of traumatic knee osteoarthritis, conducted in collaboration with Artialis SA, on PLOS ONE journal.

3 07, 2020

Seal of Excellence – Certificate delivered by the European Commission – Horizon 2020

July 3rd, 2020|0 Comments

Following evaluation by an international panel of independent experts, Regulaxis research was scored as a high-quality project proposal in a highly competitive evaluation process.

This proposal is recommended for funding by other sources, since Horizon 2020 resources available for this specific Call were already allocated following a competitive ranking.

The project proposal:  “REG-O3 Treatment of gonarthrosis […]

22 10, 2019

2019 – Regulaxis et Biocitech

October 22nd, 2019|0 Comments

Une histoire de biotechnologies innovantes
Basé à Biocitech, le parc technologique des Sciences de la Vie, juste à côté de Paris, Regulaxis est une entreprise engagée dans la recherche, le développement et la concession de licences de molécules synthétiques innovantes destinées à être utilisées en thérapie humaine.

Sa mission est d’octroyer des licences de molécules innovantes […]

10 07, 2019

2019 – Le Figaro Economie – RDV PME

July 10th, 2019|0 Comments

Regulaxis’ President Claude Carelli and the COO Christelle Vêtu participated to the RDV PME by Le Figaro Economie
This interview is focused on the research and development in the field of bioscience. In particular Regulaxis present a new innovative compound, REGO3, for the treatment of arthroses.


Follow the full article to Le Figaro Economie


30 05, 2019

2019 – Sendai, Japan – EU-Japan Industrial Cooperation

May 30th, 2019|0 Comments

Regulaxis is very proud to be the only French company selected by the EU-Japan Industrial Cooperation Center to be part of the European delegation !
Thank you also to Miyagi province officials and Jetro for receiving us and meeting top industrial companies in Sendai.


Dr. Matthieu Chareyre, our Executive Director of Industrial Operations, represented Regulaxis to this […]

8 04, 2019

2019 – Paris, France – ANRT – CLUB PME – ETI

April 8th, 2019|0 Comments

Lors de la séance du 8 Avril du CLUB PME – ETI Claude CARELLI, Président et CEO de Regulaxis a présenté son entreprise et son « business model ». Les membres du Club l’ont « challengé » pour qu’il récolte le fruit de ce «brainstorming » collectif.
Engagée dans la R&D, Regulaxis développe des molécules […]

10 12, 2018

2018 – Regulaxis moves to La Défense !

December 10th, 2018|0 Comments


The offices of the Regulaxis Management Office are located at the feet of La Défense, the business district located in the Metropole du Grand Paris.

15 06, 2018

2018 – Partnership between REGULAXIS and ARTIALIS

June 15th, 2018|0 Comments

REG-O3, the innovative therapeutic treatment for Osteoarthritis will be tested in Liège !:
Artialis, specialist in the study of the musculoskeletal disorders and Regulaxis, an innovative French company in the treatment of osteoarthritis, announce today the signing of a 1.6 million euros contract for the preclinical and clinical development of a new molecule, Reg-O3, allowing […]